Clinicopathological impact of anti-smooth muscle antibodies in patients with non-alcoholic fatty liver disease. Issue 2 (3rd April 2019) - Elalfy, H; El-Maksoud, MA; Abed, S; El Aziz, MA; Elsamanoudy, AZ; Abo El-khair, S M; Mohamed, MA; Elkashef, W; Zalata, K; Farag, R; Arafa, M